Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.

Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Mol Cancer Res (2016) 0.78

Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study. Sci Rep (2017) 0.75

Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? Cancer (2016) 0.75

Untangling ccRCC prognosis with SLINKY. Oncotarget (2017) 0.75

Molecular portraits of human breast tumours. Nature (2000) 94.14

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19

Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03

Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet (2014) 5.74

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02

ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol (2014) 4.00

Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature (2014) 3.80

Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med (2012) 2.76

Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol (2011) 2.55

Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol (2006) 2.50

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer (1998) 2.27

The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell (2014) 2.21

Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95

A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. J Urol (2011) 1.91

Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Nucl Med Commun (2012) 1.58

PET/MRI for neurologic applications. J Nucl Med (2012) 1.55

Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol (2002) 1.50

Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res (2005) 1.48

Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene (2005) 1.45

Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT. Eur J Nucl Med Mol Imaging (2012) 1.34

Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur Urol (2014) 1.21

The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med (2014) 1.16

Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer (2010) 1.13

Renal cancer biomarkers: the promise of personalized care. BMC Med (2012) 1.08

Heterogeneity and renal mass biopsy: a review of its role and reliability. Cancer Biol Med (2014) 0.93

Kidney cancer. Urol Oncol (2012) 0.91

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med (2013) 0.90

Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematol Oncol Clin North Am (2011) 0.81

The role of functional imaging in the era of targeted therapy of renal cell carcinoma. World J Urol (2013) 0.79

Improving diversity, inclusion, and representation in radiology and radiation oncology part 1: why these matter. J Am Coll Radiol (2014) 1.74

Improving diversity, inclusion, and representation in radiology and radiation oncology part 2: challenges and recommendations. J Am Coll Radiol (2014) 1.68

Counterpoint: Diversity and Inclusion: Works in Progress. J Am Coll Radiol (2015) 0.75

Increased Cortical Cerebral Blood Flow in Asymptomatic Human Immunodeficiency Virus-Infected Subjects. J Stroke Cerebrovasc Dis (2016) 0.75